PFE - Pfizer Inc.

NYSE - NYSE Delayed Price. Currency in USD
32.67
+1.77 (+5.73%)
At close: 4:02PM EDT

32.70 +0.03 (0.09%)
After hours: 7:56PM EDT

Stock chart is not supported by your current browser
Previous Close30.90
Open31.05
Bid32.60 x 900
Ask32.85 x 800
Day's Range31.05 - 32.85
52 Week Range27.88 - 44.56
Volume28,320,406
Avg. Volume32,222,470
Market Cap181.241B
Beta (5Y Monthly)0.69
PE Ratio (TTM)11.40
EPS (TTM)2.87
Earnings DateApr 27, 2020
Forward Dividend & Yield1.52 (4.92%)
Ex-Dividend DateJan 29, 2020
1y Target Est41.93
  • Yahoo Finance Presents: Senator Kirsten Gillibrand
    Yahoo Finance Video

    Yahoo Finance Presents: Senator Kirsten Gillibrand

    In this episode of Yahoo Finance Presents, Rick Newman speaks with New York Senator Kirsten Gillibrand about Congress' coronavirus relief bill and what lawmakers are doing to protect NY.

  • GuruFocus.com

    US Indexes Close Higher Monday

    S&P; 500 up 3.35% Continue reading...

  • Barrons.com

    When Will a Coronavirus Vaccine be Ready? These 9 Programs Are Making Progress.

    There are currently at least 47 Covid-19 vaccine programs under way. Here are some to keep an eye on.

  • Is AbbVie Stock A Buy As Coronavirus Worries Hammer The Market?
    Investor's Business Daily

    Is AbbVie Stock A Buy As Coronavirus Worries Hammer The Market?

    AbbVie stock initially fell on its $63 billion plan to buy Botox-maker Allergan, which helps the pharmaceutical company diversify as Humira patents expire. So, is ABBV stock a buy right now?

  • Mylan offers concessions to address EU concerns about Pfizer deal
    Reuters

    Mylan offers concessions to address EU concerns about Pfizer deal

    Generic drugmaker Mylan NV has offered concessions to address European Union antitrust concerns about its bid for Pfizer's off-patent branded drugs business Upjohn, a filing on the European Commission site showed on Monday. U.S. drugmaker Pfizer announced the deal in July as part of a strategy allowing it to focus on its more profitable newer medicines. The European Commission set an April 22 deadline for its decision after Mylan put in its offer on March 27.

  • Drug makers on shaky ground as clinical trials are postponed and drug launches delayed amid pandemic
    MarketWatch

    Drug makers on shaky ground as clinical trials are postponed and drug launches delayed amid pandemic

    Bristol-Myers Squibb Co.’s decision to hold off launching Zeposia, its newly approved multiple sclerosis treatment, underscores how disruptive the COVID-19 pandemic is to a trillion-dollar industry that relies heavily on collaborative working and meeting milestones that satiate investors.

  • GuruFocus.com

    Covid-19 Could Benefit Generic Drug Companies

    Pricing is increasing for makers of copycat medicines Continue reading...

  • Barrons.com

    Coronavirus Means Fewer Stock Buybacks, Analyst Says. It Could Shake Up Biopharma.

    As the government prepares to bail out industries amid the Covid-19 pandemic, stock buybacks are falling out of favor. One sector that does a lot of repurchases? The biopharma industry.

  • Business Wire

    Pfizer Completes $1.25 Billion Sustainability Bond for Social and Environmental Impact

    Pfizer Inc. (NYSE: PFE) today announced the completion of a $1.25 billion ten-year "sustainability" bond paying interest semi-annually of 2.625 percent and maturing April 1, 2030. This is Pfizer’s first-ever sustainability bond and a first for a biopharmaceutical company.

  • Barrons.com

    Pfizer and Mylan Postpone Upjohn Deal. Analysts Aren’t Worried.

    The news is the latest sign of the dramatic impact that the Covid-19 pandemic is having across the health care industry.

  • Zacks Value Trader Highlights: eBay, Pfizer, JPMorgan Chase, Intuitive Surgical and Edwards Lifesciences
    Zacks

    Zacks Value Trader Highlights: eBay, Pfizer, JPMorgan Chase, Intuitive Surgical and Edwards Lifesciences

    Zacks Value Trader Highlights: eBay, Pfizer, JPMorgan Chase, Intuitive Surgical and Edwards Lifesciences

  • Pfizer Stock Falls 3%
    Investing.com

    Pfizer Stock Falls 3%

    Investing.com - Pfizer (NYSE:PFE) Stock fell by 3.17% to trade at $30.68 by 09:30 (13:30 GMT) on Friday on the NYSE exchange.

  • 5 Superstar Stocks on Sale During the Coronavirus Crisis
    Zacks

    5 Superstar Stocks on Sale During the Coronavirus Crisis

    Stocks are the only thing people won't buy when they go on sale. But with stocks in a bear market, now's your chance to pick up some of the best companies.

  • Pfizer's Upjohn Combo With Mylan Is Delayed — What That Means For PFE Stock
    Investor's Business Daily

    Pfizer's Upjohn Combo With Mylan Is Delayed — What That Means For PFE Stock

    Pfizer stock could see some gains in 2020 if it makes progress on a coronavirus vaccine with BioNTech. But its Upjohn merger with Mylan is now delayed. Is Pfizer stock a buy now?

  • Pfizer Stock Rises 5%
    Investing.com

    Pfizer Stock Rises 5%

    Investing.com - Pfizer (NYSE:PFE) Stock rose by 5.31% to trade at $31.36 by 13:48 (17:48 GMT) on Thursday on the NYSE exchange.

  • $110M injection powers up Peninsula vaccine maker — but not for COVID-19
    American City Business Journals

    $110M injection powers up Peninsula vaccine maker — but not for COVID-19

    The vaccine, expected to produce data from a clinical trial in 2022, is designed to essentially carry 24 vaccines in one against pneumonia.

  • The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Xencor Licenses Tech To Vir For COVID-19 Treatment, Delay In Pfizer's Upjohn-Mylan Merger
    Benzinga

    The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Xencor Licenses Tech To Vir For COVID-19 Treatment, Delay In Pfizer's Upjohn-Mylan Merger

    Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 25.) * Ra Pharmaceuticals Inc (NASDAQ: RARX)Down In The Dumps (Biotech stocks that hit 52-week lows March 25.) * Anixa Biosciences Inc (NASDAQ: ANIX) * IMMUTEP LTD/S ADR (NASDAQ: IMMP) (reacted to breast cancer trial readout) * PLx Pharma Inc (NASDAQ: PLXP) * Taro Pharmaceutical Industries Ltd. (NYSE: TARO)Stocks In Focus Quidel COVID-19 Detection Assay Obtains Expanded EUA, CE Mark Approval Quidel Corporation (NASDAQ: QDEL) said its Lyra SARS-CoV-2 Assay has received expanded Emergency Use Authorization from the FDA to allow testing with three additional thermocyclers, namely Applied Biosystems' 7500, Roche Holdings AG's (OTC: RHHBY) LightCycler 480 and Qiagen NV's (NYSE: QGEN) Rotor Gene Q.Quidel said the initial EUA awarded allowed qualitative detection of nucleic acid from SARS-CoV-2 in nasopharyngeal or oropharyngeal swab specimens from patients suspected of COVID-19. The expanded authorization includes nasal and nasal turbinate swabs.Quidel also said it received the CE-Mark on March 25, which will allow it market and sell the Lyra SARS-CoV-2 Assay in Europe as well as other countries that accept CE Mark.Alector Out-Licenses China Rights of AL008 In Oncology To Innovent Biologics Alector Inc (NASDAQ: ALEC) and Hong Kong-listed biopharma Innovent Biologics said they have entered into a licensing agreement to develop and commercialize an anti-SIRP-alpha antibody AL008 for the treatment of oncology indications in China.The companies did not disclose the financial terms of the deal. The agreement gives Innovent the responsibility of leading development and commercialization of the investigational compound in China, while Alector is in charge of developmental activities outside of China.See also: The Week Ahead In Biotech: Bristol-Myers, Rockwell Medical Await FDA Decisions, COVID-19 Updates In Focus Bristol-Myers Squibb Receives FDA Nod For Celgene's Multiple Sclerosis Drug Bristol-Myers Squibb Co (NYSE: BMY) announced FDA approval for ozanimod 0.92 mg as a treatment option for patients with relapsing forms of multiple sclerosis.In premarket trading Thursday, Bristol-Myers Squibb shares were adding 1.52% to $50.10.Cerecor To Test Role Of Inflammatory Cytokinin In COVID-19-Induced Acute Respiratory Distress Cerecor Inc (NASDAQ: CERC) said it plans to explore the role of an inflammatory cytokine -- LIGHT -- in patients with COVID-19-induced acute respiratory distress. It said it will use its proprietary free LIGHT assay as well as multiple assay to determine if there are differences in LIGHT levels and other inflammatory markers, including IL-18 and IFN-g, in patients with mild-to-moderate vs. severe disease with Acute Lung Injury or Acute Respiratory Distress Syndrome.Grifols To Develop Hyperimmune Globulin For COVID-19 Grifols SA - ADR (NASDAQ: GRFS) said it has entered a formal collaboration agreement with the U.S. BARDA, the FDA and other federal public health agencies to collect plasma from convalescent COVID-19 patients and process this specific plasma into a hyperimmune globulin.The company also said it will support the necessary preclinical and clinical studies to determine if anti-SARS-CoV-2 hyperimmune globulin therapy can be used to treat COVID-19 disease.In Spain, Grifols is working on a clinical trial with inactivated plasma from recovered patients through a collaboration with select donation centers and public hospitals.View more earnings on IBBThe company also said it has accelerated the development and validation of a proprietary technology transcription-mediated amplification-based diagnostic procedure to detect the virus, with a sensitivity equivalent or even superior to that of PCR test.The stock was rising 10.47% to $19.63 in premarket trading.Pfizer, Mylan Announce Delay In Merger Of Generic Businesses Pfizer Inc. (NYSE: PFE) and Mylan NV (NASDAQ: MYL) announced the proposed merger between Mylan and Pfizer's generic unit Upjohn will now close in the second half of 2020 due to the unprecedented circumstances surrounding the COVID-19 pandemic, including associated delays in the regulatory review process. The companies initially had a closing deadline of mid-2020.Biopharmx Gets Delisting Notice From NYSE American Specialty pharma company Biopharmx Corp (NYSE: BPMX) said it received a notification from NYSE American LLC on March 24 regarding its determination to delist the company's shares from the exchange. The decision is due to the company's non-compliance with certain continued listing standards.Biopharmx said it will appeal the delisting notice. The shares, according to the company, will continue to trade on the exchange during the appeal period.The company also clarified that the delisting does not affect its business operations, its intention to merge with Timber Pharma announced Jan. 28 or its SEC reporting requirements,The stock was down 2.83% at 28 cents at the time of publication.Xencor, Vir Agree To License Technology To Extend Half-Life Of COVID-19 Treatment Candidates Xencor Inc (NASDAQ: XNCR) said it entered into a technology license agreement with Vir Biotechnology Inc (NASDAQ: VIR) that provides Vir non-exclusive access to Xencor's Xtend Fc technology to extend the half-life of novel antibodies Vir is investigating as a potential treatment for COVID-19."Xtend Fc technology has demonstrated, in multiple antibodies and through numerous human clinical trials, the ability to extend antibody drug half-life and reduce dosing frequency in patients, an important feature in anti-viral therapy for pandemic use," Xencor CEO Bassil Dahiyat said in a statement. The companies did not disclose the financial terms of the deal.Vir shares were trading 3.22% higher at $31.74 in Thursday's premarket session.Earnings Biocept Inc's (NASDAQ: BIOC) fourth-quarter revenue climbed 108% year-over-year to $1.8 million. The net loss narrowed significantly from $1.43 per share to 20 cents per share. Analysts estimated a loss of 10 cents per share.The stock was trading 8.57% higher at 38 cents at the time of publication. On The Radar PDUFA Dates IntelGenx Technologies Corp.'s (OTC: IGXT) NDA for rizaport versafilm for the treatment of acute migraine is pending before the FDA, with the target action day fixed for Thursday. The company had faced three rejections for the investigational drug in the past.Earnings * Celsion Corporation (NASDAQ: CLSN) (before the market open) * Entera Bio Ltd (NASDAQ: ENTX) (before the market open) * TFF Pharmaceuticals Inc (NASDAQ: TFFP) (before the market open) * IGM Biosciences Inc (NASDAQ: IGMS) (after the close) * NovaBay Pharmaceuticals, Inc. (NYSE: NBY) (after the close) * Vermillion, Inc. (NASDAQ: VRML) (after the close) * aTyr Pharma Inc (NASDAQ: LIFE) (after the close)Related Link: Hoth Therapeutics Shares Jump On COVID-19 Vaccine Development Plans See more from Benzinga * The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Mylan delays merger with Upjohn due to COVID-19 pandemic
    American City Business Journals

    Mylan delays merger with Upjohn due to COVID-19 pandemic

    The Mylan NV-Upjohn merger is being pushed back into the second half of 2020 due to the COVID-19 global pandemic. Mylan NV (Nasdaq: MYL) and Pfizer Inc. (NYSE: PFE), which owns Upjohn, announced Thursday that COVID-19 is moving the expected merger date from the first half of the year and Mylan's meeting of shareholders to approve it is being moved from April 27 to June 30. Mylan and Upjohn announced last July that they would be merging to create a global pharmaceutical giant, in both generic and brand name drugs.

  • Drugmakers Mylan, Pfizer delay merger due to coronavirus outbreak
    Reuters

    Drugmakers Mylan, Pfizer delay merger due to coronavirus outbreak

    Due to restrictions on large gatherings, the general meeting of shareholders to approve certain matters for the deal to go through has been postponed to June 30, Mylan said. There were no other changes to previously announced terms or plans pertaining to the deal, previously expected to close in mid-2020, the companies said. The merger, which will bring blockbuster treatments Viagra and Lipitor from Pfizer under one umbrella with Mylan's EpiPen, is part of years-long effort by Pfizer to split into three parts - innovative medicines, lower margin off-patent drugs facing generic competition and consumer healthcare.

  • Mylan and Pfizer Provide Update Regarding Proposed Combination of Mylan and Upjohn
    PR Newswire

    Mylan and Pfizer Provide Update Regarding Proposed Combination of Mylan and Upjohn

    Mylan N.V. (Nasdaq: MYL) and Pfizer Inc. (NYSE: PFE) today announced that due to the unprecedented circumstances surrounding the COVID-19 pandemic, including associated delays in the regulatory review process, the proposed transaction involving Mylan and Upjohn, a division of Pfizer, is now anticipated to close in the second half of 2020.

  • Pfizer (PFE) Gains But Lags Market: What You Should Know
    Zacks

    Pfizer (PFE) Gains But Lags Market: What You Should Know

    Pfizer (PFE) closed at $29.75 in the latest trading session, marking a +0.17% move from the prior day.

  • Pfizer pauses new studies due to coronavirus
    Reuters

    Pfizer pauses new studies due to coronavirus

    March 25 (Reuters) - Pfizer Inc said on Wednesday it was pausing patient recruitment in new and ongoing global studies for three weeks due to the coronavirus outbreak.